Summary
This document presents the results of the Italian Health Economics Association (AIES) working group established to suggest guidelines on how to conduct economic evaluation studies of health programs. The document conceptualises such studies as part of health technology assessment carried out to provide guidance to the Italian National Health Service (INHS). The document aims to make available to public institutions, regulatory agencies and organizations operating in the health field a valid and feasible tool to make decisions more rational and more productive in terms of health gains. Overall, evidence-based medicine (EBM) is gaining ground and clinical decisions are increasingly taken on the basis of adequate scientific knowledge. The document suggests to extend the EBM approach to economic analysis and details how to do it in practice. The guidelines adopt the approach of the reference case which sets precise rules about major methodological decisions. Such an approach eases comparisons of results across studies and thus contributes to use them consistently in decision making. The reference case identifies the cost-effectiveness analysis, and in particular the incremental cost per Quality-Adjusted Life-Year (QALY), as the method to be used in the reference case in economic evaluations. The guidelines intend to stimulate the discussion among main actors and stakeholders who want to contribute to the development of rational governing tools for the INHS.
Similar content being viewed by others
Abbreviations
- ACE:
-
analisi costi-efficacia
- ACB:
-
analisi costi-benefici
- ACU:
-
analisi costi-utilità
- CDR:
-
caso di riferimento
- CDRS:
-
caso di riferimento secondo la prospettiva sociale
- EQ-5D:
-
Euro-Qol-5 dimensions
- HTA:
-
health technology assessment
- ICER:
-
rapporto incrementale costi-efficacia
- LG:
-
linee guida
- NICE:
-
National Institute for Health and Clinical Excellence
- QALY:
-
quality-adjusted life-years
- VE:
-
valutazione economica
Bibliografia
Garattini L, Grilli R, Mantovani L, Scopelliti D. A proposal for Italian guidelines in pharmacoeconomics. Pharmacoeconomics 1995; 7: 1–6
Attanasio E, Bruzzi P, Capri S, et al. Raccomandazioni per la conduzione degli studi di farmacoeconomia: la guida GISF. Mecosan 1999; 29: 65–72
Age.Na.S (Agenzia Nazionale per i Servizi Sanitari Regionali). Linea guida per la valutazione economica in un modello di SSN pubblico universale e federale. Roma: ANSSR, 2007
Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. Third edition. New York: Oxford University Press, 2005
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.01. The Cochrane Collaboration, 2008. (disponibile su www.cochrane-handbook.org)
National Institute for Health and Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal. Issue date: June 2008 (disponibile su http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf)
Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. Third edition. Ottawa: CADTH, 2006
Centre for Reviews and Dissemination. CRD guidance for undertaking reviews in healthcare. York: CRD University of York, 2008 (disponibile su: http://www.york.ac.uk/inst/crd/crdreports.htm)
Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005; 9: 1–148
Brooks R. EuroQol: the current state of play. Health Policy 1996; 37: 53–72
Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21: 271–92
Furlong W, Feeny D, Torrance GW, Barr RD. The Health Utility Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 2001; 33: 375–84
Adam T, Koopmanschap MA, Evans DB. Cost-effectiveness analysis: can we reduce variability in costing methods? Int J Technol Assess Health Care 2003; 19: 407–20
McCabe C, Claxton K, Culyer A. The NICE cost-effectiveness threshold. What it is and what that means. Pharmacoeconomics 2008; 26: 733–44
Sculpher MJ, Pang FS, Manca A, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess 2004; 8: 1–192
Author information
Authors and Affiliations
Corresponding author
Additional information
I membri del gruppo di lavoro dell’Associazione Italiana di Economia Sanitaria (AIES) sono riportati alla fine dell’articolo.
Rights and permissions
About this article
Cite this article
Fattore, G. Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. Pharmacoeconomics-Ital-Res-Articles 11, 83–93 (2009). https://doi.org/10.1007/BF03320660
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03320660